Abstract: Objective：To obtain the clinical value of atosiban, ritodrine treatment in late abortion and preterm labour of twin pregnancy. Methods：A retrospective analysis was made of 85 women with late abortion and threatened preterm labor who were treated in the Second Affiliated Hospital of Zhengzhou University from January 2015 to January 2017. According to the drug use situation, they were divided into atoxiban group of 20 cases, ritodrine group of 25 cases, and ritodrine combined with atoxiban group of 40 cases (combined medication group). To observe the success rate, prolonged gestation week, neonatal condition, postpartum bleeding rate and adverse drug reaction. Results：The effect time of atociban was short, there was statistically significant difference between the two groups (all P＜0.05). There were no significant difference between the success rate in three groups ( χ2=0.30, P=0.86). There was no significant difference in neonatal birth weight and neonatal asphyxia rate (all P＞0.05). None of the 3 groups had postpartum hemorrhage. High risk of adverse drug reactions of ritodrine happened in patients, who had the albumin level is lower than 30 g/L, HGB≤100 g/L and the basic heart rate ≥100/min. Conclusions：Atociban can be considered as a first-line medicine in the twin pregnacy with effective contraction, with the albumin level ≤30 g/L, HGB≤100 g/L and the basic heart rate ≥100/min.

Key words: Pregnancy, multiple, Twins, Premature birth, Ritodrine, Calcium channel blockers, Atosiban